Belagenpumatucel-L therapeutic tumour cell vaccine for non-small cell lung cancer

Despite overall survival results from second-line treatment with the therapeutic tumour cell vaccine, belagenpumatucel-L, did not meet predefined end point in the entire population of patients with late stage non-small cell lung cancer, the phase III STOP trial identified subgroups of patients who derived notable clinical benefit. Significantly prolonged overall survival with belagenpumatucel-L were demonstrated in stage IIIB/IV patients who began belagenpumatucel-L within 12 weeks of the completion of front-line chemotherapy. Read more here.